RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
|Videos|September 1, 2021
Hopeful Outcomes for the Pfizer-BioNTech COVID-19 Vaccine
Pharmacy Times spoke with Ilisa Bernstein, APhA senior vice president, Pharmacy Practice and Government Affairs, about the latest FDA approval of the Pfizer-BioNTech COVID-19 vaccine.
Advertisement
Pharmacy Times spoke with Ilisa Bernstein, APhA senior vice president, Pharmacy Practice and Government Affairs, about the latest FDA approval of the Pfizer-BioNTech COVID-19 vaccine.
Bernstein discussed what this approval means to the pharmacy community, what she hopes to continue seeing for pharmacists, the COVID-19 Vaccine Education and Equity Project, and more.
Advertisement
Related to this article
Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5